कंपनी का अवलोकन
Generation Bio Co. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it discovers, develops, and commercializes redosable therapeutics designed to reprogram T cells in vivo. The company's primary objective is to reduce or eliminate the production and persistence of autoreactive T cells by developing cell-targeted lipid nanoparticles (ctLNP) for the selective delivery of small molecules. As of the latest data, the company holds a market capitalization of $35.98M and reports annual revenue of $15.27M, employing a workforce of 115 individuals. These financial figures indicate that the organization operates on a micro-cap scale, reflecting the early-stage nature of its commercialization efforts and the significant capital requirements typical for biotechnology firms developing novel cell therapies. The combination of a modest market cap and current revenue stream suggests the company is still in a phase where operational costs and research expenditures likely outpace income generation, which is characteristic of the sector before widespread product approval or market penetration.
वित्तीय स्वास्थ्य
The company reported a revenue of $15.27M over the trailing twelve months, yet recorded a net income of -$62,627,000 and an EBITDA of -$76,380,000. The substantial gap between the positive revenue of $15.27M and the significant net loss reveals a highly expansive cost structure typical of biotechnology entities, where research and development expenses, along with clinical trial costs, far exceed current sales figures. Furthermore, the company generated free cash flow of -$40,196,752, indicating that its current financial flexibility is constrained by heavy cash burn, necessitating a reliance on existing cash reserves or external financing to sustain operations. The margin profile is particularly stark, with a gross margin of -212.2%, an operating margin of -2020.0%, and a profit margin of 0.0%, which collectively indicate that the cost of goods sold and operating expenses are disproportionately high relative to the revenue generated. In terms of liquidity and leverage, the company holds cash of $89.62M against total debt of $26.10M, resulting in a debt-to-equity ratio of 51.61, suggesting a balance sheet that maintains significant cash reserves despite negative earnings. The current ratio stands at 4.44, which indicates a robust short-term liquidity position where current assets are more than four times current liabilities, providing a buffer against immediate financial obligations. Finally, the return on equity is -80.8% and the return on assets is -27.4%, metrics that reveal that management effectiveness is currently challenged by the inability to generate positive returns on the capital base due to the inherent losses in the development phase of the business.
मूल्यांकन आकलन
The valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to negative earnings and a forward P/E of -3.99, which implies that the market is pricing in a negative earnings trajectory or expects earnings to remain negative in the near term. The price-to-book ratio is 0.71, indicating that the stock is trading below its book value, which often suggests that the market perceives high risks or that the intangible assets associated with the biotechnology assets are not fully captured in the book value. Alternative valuation measures include a price-to-sales ratio of 2.36 and an EV/EBITDA of 0.36, which suggest that the company is being valued based on its sales potential rather than current profitability, a common approach for pre-revenue or loss-making biotechnology firms. The stock's price volatility is evident from its 52-week trading range, with a high of $7.60 and a low of $3.00, meaning the current price sits within a wide band of fluctuation relative to these historical extremes. Additionally, the company has a beta of 2.01, which signifies that the stock is more than twice as volatile as the broader market, reflecting the high risk profile associated with small-cap biotechnology equities.
Growth & Income
The company experienced a revenue growth rate of -78.9% year-over-year, while earnings growth is N/A, indicating that the company is currently shrinking in terms of top-line revenue rather than expanding its sales base. Since the company is not a dividend payer, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders, which is consistent with a firm that must retain all capital for research and development. Consequently, the company reinvests its limited positive cash flows and utilizes its substantial cash reserves to fund ongoing operations and therapeutic development rather than paying out income to investors. The overall growth and income profile is characterized by significant revenue contraction and a lack of dividend income, positioning the asset as a speculative investment reliant on future clinical success or new product approvals to reverse the current negative growth trend.